Showing 1 - 10 of 59,494
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug reactions (ADRs) by modeling the interaction between a regulator (the FDA) and a pharmaceutical firm. Promotion-driven market expansions enhance profitability yet may involve the risk of...
Persistent link: https://www.econbiz.de/10014137229
The theoretical relationship between market structure (number of firms) and conduct (pricing behavior) of the generic drug industry was investigated. The effects of qualitative variables such as therapeutic category, duration of use, popularity, and market entry aggressiveness on the...
Persistent link: https://www.econbiz.de/10013128541
Research on the launch of new products in the international realm is scarce. The present paper is the first to document how launch window (difference in months between the first worldwide launch and the subsequent launch in a specific country) and launch price are interrelated and how regulation...
Persistent link: https://www.econbiz.de/10013114669
Persistent link: https://www.econbiz.de/10003794578
Persistent link: https://www.econbiz.de/10010467440
Purpose – The purpose of this paper is to use results from a comprehensive analysis of a physician-prescribing model to draw guidelines on how to promote a new drug in the presence of competing older drugs, in a chronic therapeutic state.Design/methodology/approach – The authors use an...
Persistent link: https://www.econbiz.de/10013115780
The purpose of this paper is to investigate the wealth effects of the issuance of guidelines by the Office of Inspector General (OIG) to encourage pharmaceutical manufacturers to use internal controls or self-regulation “to efficiently monitor adherence to applicable statutes, regulations, and...
Persistent link: https://www.econbiz.de/10013068445
Crestor, an important but controversial cholesterol-lowering drug, is contraindicated for use by senior and Asian patients. In this paper, we exploit this fact and a unique doctor-level prescription and advertising (detailing, to be exact) exposure data for statin drugs to examine the hypothesis...
Persistent link: https://www.econbiz.de/10012940309
Pharmaceutical markets experience the entry of numerous generic firms upon expiration of the brand firm's patent. In this paper, we take a close look at competition among the generic entrants during the first three years after patent expiration and examine whether there is a first mover...
Persistent link: https://www.econbiz.de/10012709667